Adil I. Daud

Adil I. Daud

Hematology | Oncology
1600 Divisadero St
Fl 3
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications

The paradox of escalating immunotherapy for uveal melanoma liver metastases.

The paradox of escalating immunotherapy for uveal melanoma liver metastases.

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association
Published: April 22, 2026

Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 04, 2025

Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma.

Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma.

Journal: BMC cancer
Published: August 28, 2025

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

Journal: Pigment cell & melanoma research
Published: August 22, 2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: July 04, 2025

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Journal: Cancer
Published: April 08, 2025

Longitudinal Evaluation of Immune Checkpoint Inhibitor-Induced Fatigue Syndrome by Rest, Stress, and Speckle-Tracking Strain Echocardiography.

Longitudinal Evaluation of Immune Checkpoint Inhibitor-Induced Fatigue Syndrome by Rest, Stress, and Speckle-Tracking Strain Echocardiography.

Journal: Echocardiography (Mount Kisco, N.Y.)
Published: January 06, 2025

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.

Journal: The Journal of clinical investigation
Published: October 15, 2024

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 12, 2024

PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

Journal: Nature communications
Published: August 05, 2024

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.

Journal: Cancer journal (Sudbury, Mass.)
Published: March 25, 2024

Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.

Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.

Journal: Cancers
Published: January 31, 2024
Showing 1-12 of 164

Last Updated: 09/26/2026